In the evolving field of biochemical research Thrombospondin-targeting TAX2 peptide impairs tumor , the TAX2 peptide has become a subject of significant interest for those of us who follow advanced protein-based studies. As someone deeply invested in peptide synthesis and molecular biology, I have spent considerable time analyzing the literature surrounding this specific compound. It is important to note that my interest is strictly scientific and laboratory-based; I do not provide or endorse any medical or clinical advice.
Understanding the TAX2 Peptide Structure
The TAX2 peptide is a fascinating subject of study due to its unique chemical profile. With a molecular formula of C51H86N14O19S2 and a molecular weight of approximately 1263.44, it stands out as a highly specialized molecule.
The most prominent feature of this compound is that the TAX2 peptide is a cyclic peptide that functions as an orthosteric antagonist. Specifically, it is designed to selectively prevent TSP-1 binding to CD47. By modulating the interaction between Thrombospondin-1 (TSP-1) and the CD47 receptor, researchers have been able to observe distinct biologic by A Jeanne·2021·Cited by 24—TAX2 peptideis a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its al behaviors in diverse experimental models.
Experimental Observations and Findings
In my review of the available academic data, several key findings highlight why this entity is so frequently cited in modern research papers:
* Anti-Angiogenic Properties: Research indicates that the molecule exhibits unexpected anti-angiogenic properties in vitro. This is a critical observation for those studying vascular development in non-clinical models.
* Tumor Vascularization: Studies documenting TAX2 in vivo administrations highly disturb syngeneic melanoma tumor vascularization. The resulting disruption of Identification and characterization of TAX2 peptides ten leads to significant necrosis within the studied tissue, providing a clear visual of its potency.
* Multifaceted Efficacy: It is widely reported that the TAX2 displays exciting antiangiogenic, antitumor, and antimetastatic properties across various xenograft and allograft models, including studies on melanoma and pancreatic tissue.
* Platelet Interaction: Beyond tumor studies, it has been observed that the TAX2 peptide strongly decreases platelet aggregation and inhibits interaction with collagen, particularly under arterial shear conditions. This highlights the molecule's versatility in biochemical pathway modulation.
Contextualizing TAX2 in Broader Peptide Research
When comparing this compound to other agents, such as the TAT-HA2 fusion peptide—which is primarily r by A Jeanne·2021·Cited by 24—TAX2 peptideis a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47.Read more ecognized as a delivery agent—it becomes clear that TAX2 serves a more targeted, receptor-specific purpose. While some may confuse this with the one of the largest families of neuropeptides (the tachykinin family), it is essential to distinguish that TAX2 is a specific, CD47-derived peptide.
Furthermore, the thrombospo Peptides in cancer research - Bachem ndin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models, such as those used for childhood neuroblastoma. This has paved the way for its role as a matrix-targeted TAX2 therapeutic peptide in controlled laboratory settings.
Final Observations
For those of us tracking the development Molecular characterization of TAX2 drug candidate. (a) of specialized biochemicals, the TAX2 peptide represents a sophisticated intersection of structural chemistry and receptor biology. Its ability to act as a precise antagonist for the TSP-1:CD47 pathway makes it a valuable tool for researchers aiming to understand complex signaling pathways in controlled environments.
As with any specialized research chemical, the focus remains on its structural integrity and its predic by A Jeanne·2021·Cited by 24—TAX2 peptideis a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its table interactions within the biological matrices it is designed to influence. My exploration into this compound confirms its status as a robust candidate for continued, rigorous scientific investigation.